| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: XGEN |
| Security Type |
Common Stock |
| Lead Underwriter |
Thomas Weisel Partners LLC |
| Days In Registration |
105 |
| Date Filed |
2-Apr-2004 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Biotechnology company |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
14.68M |
| Contact |
- |
| Number of Employees |
72 |
|
| Original Filing Information |
| US |
| Shares Filed |
4.5M |
| Secondary Shares Filed | 1.0M |
| · As a Percent |
22.2 |
| Primary Shares Filed |
3.5M |
| · As a Percent |
77.8 |
| Overallotment Shares Filed |
630.0K |
| File Amount |
$45.0M |
| File Price Range |
$11.00 - $9.00 |
| File Mid Price |
$10.00 |
Current Filing Information
(Amended 15-Jul-2004) |
|
US |
|
Shares Filed |
4.5M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
4.5M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$36.0M |
| · % Change from Original |
-20.0 |
| File Price Range |
$8.00 - $8.00 |
| File Mid Price |
$8.00 |
|
